“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

Alliance launches trial to study exercise in cancer patients

The Alliance for Clinical Trials in Oncology has launched a new clinical trial seeking to evaluate the feasibility of delivering a structured exercise program entirely through telehealth for patients with cancer receiving chemotherapy with the ultimate goal of reducing fatigue and disability.

November 14, 2025

Vol.51 No.42

Clinical Roundup

Researchers develop technique to track chemotherapy drug inside cells

Scientists face limitations in determining the results of drug effectiveness, as well as ensuring even distribution among all cancer cells because of the highly compact nature of tumors. Researchers are working to change that by giving chemotherapy drugs a kind of chemical “signal” to track them inside cells.

October 31, 2025

Vol.51 No.40

Clinical Roundup

Study points to potential cause for “chemo brain”

Cancer is a challenging enough diagnosis, but many patients are dealt a second blow, even as they heal: chemo brain.

October 17, 2025

Vol.51 No.38

Clinical Roundup

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Oxaliplatin-based chemotherapy significantly improves survival only in stage 3 colorectal cancer patients aged 70 or younger, according to a study conducted by researchers at Korea University Guro Hospital and Korea University College of Medicine. For patients over 70, the drug offered no survival advantage and led to higher rates of treatment discontinuation due to toxicity.

September 26, 2025

Vol.51 No.35

Cancer Policy

Trump administration wants to rebuild stockpile of APIs to address drug shortages

To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term.

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum.

September 05, 2025

Vol.51 No.32

“Historic” cisplatin shortage leaves oncologists guessing whether they will have enough to treat the next patient

YOU MAY BE INTERESTED IN

Alliance launches trial to study exercise in cancer patients

Researchers develop technique to track chemotherapy drug inside cells

Study points to potential cause for “chemo brain”

Korean researchers find CRC patients over 70 years don’t stand to benefit from chemo

Trump administration wants to rebuild stockpile of APIs to address drug shortages

MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds

Renew today!

Subscriber content

Never miss an issue!

Login